Loading...
Loading...
PASG| Name | Value |
|---|---|
| Revenues | 5.9M |
| Cost of Revenue | 0.8M |
| Gross Profit | 5.1M |
| Operating Expense | 17.6M |
| Operating I/L | -18.4M |
| Other Income/Expense | 1.7M |
| Interest Income | 1.5M |
| Pretax | -16.8M |
| Income Tax Expense | 3.5M |
| Net Income/Loss | -16.8M |
Passage Bio, Inc. is a genetic medicines company specializing in developing transformative therapies for central nervous system diseases. The company's product pipeline includes PBGM01 for infantile GM1, PBFT02 for FTD-GRN, and PBKR03 for infantile Krabbe disease. Additionally, Passage Bio is developing PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. The company generates revenue through strategic research collaborations and development services agreements with partners such as the University of Pennsylvania's Gene Therapy Program and Catalent Maryland, Inc.
